拉马特佩隆在双相障碍躁狂发作中迅速缓解症状
Lumateperone Brings Rapid Relief in Bipolar Mania
拉马特佩隆在双相障碍躁狂发作的 III 期试验中表现出快速疗效,显著改善症状,且安全性良好。研究显示,治疗 3 天后症状明显改善,且疗效持续至第 22 天。
研究显示拉马特佩隆在治疗双相障碍躁狂发作方面具有快速疗效,且安全性良好。
— The atypical antipsychotic improved symptoms within 3 days
November 6, 2026 • 3 min read
Lumateperone (Caplyta) rapidly improved symptoms of acute mania associated with bipolar I disorder, a phase III trial showed.
Among 351 patients with or without mixed features, lumateperone demonstrated superiority over placebo in reducing the Young Mania Rating Scale (YMRS) total score by day 22 (least squares mean difference -3.7, 95% CI -5.61 to -1.86, P<0.0001), with significant differences noted by day 3 and maintained from week 1 onward, reported Roger S. McIntyre, MD, of the University of Toronto, and colleagues.
Meeting the key secondary endpoint, the atypical antipsychotic also led to greater improvement in overall illness severity, demonstrating superiority over placebo in change in Clinical Global Impression-Severity (CGI-S) score (least squares mean difference -0.4, 95% CI -0.58 to -0.17, P=0.0003).
The study was presented at the Neuroscience Education Institute (NEI) Fall Congress in Colorado Springs, Colorado.
"The overall clinical meaningfulness was not only observed rapidly on day 3, which was the second day post-treatment, but also response rates that translate into a number needed to treat of 5, indicating clinical relevance," McIntyre told MedPage Today.
"These efficacy findings alongside low rates of treatment-emergent adverse events and discontinuation rates due to adverse events, similar to placebo, underscore the clinical utility of lumateperone and why it would be a preferred treatment in adults presenting with mania with or without mixed features," he said.
This was the second pivotal phase III study evaluating lumateperone for acute bipolar mania. Its findings replicate and reinforce results from an identically designed sister trial reported in September at Psych Congress.
The once-daily, oral antipsychotic is not currently approved for the treatment of manic episodes associated with bipolar I disorder, but is approved for adults with bipolar depression (as monotherapy or adjunctive therapy with lithium or valproate), for schizophrenia, and as an adjunctive therapy with antidepressants for major depressive disorder.
While the mechanism of action of lumateperone is unknown, its efficacy could be mediated through a combination of antagonist activity at central serotonin 5-HT2A receptors and partial agonist activity at central dopamine D2 receptors.
"With respect to existing knowledge of lumateperone, these data establish the efficacy of lumateperone across the mood spectrum," said McIntyre.
"Notwithstanding options available for the treatment of bipolar mania with and without mixed features in adults, there remains a need for treatments that are rapidly efficacious with meaningful improvements for what effectively is a medical emergency, that is, bipolar mania," he noted.
Michael Thase, MD, of the University of Pennsylvania in Philadelphia, previously underscored in a statement from the drugmaker that "mania is among the most dangerous and worrisome phases of bipolar disorder, and treating it effectively takes more than partial or temporary relief of symptoms; it means bringing the episode itself under control as quickly as possible."
For the double-blind trial, eligible patients diagnosed with bipolar I disorder and an acute manic episode with or without mixed features (symptoms of mania or hypomania along with symptoms of depression) according to DSM-5-TR criteria were randomized 1:1 to receive 3 weeks of either lumateperone 42 mg or placebo. Treatment began in an inpatient setting, with patients eligible for discharge to outpatient care after week 2.
Average patient age was 46.1 years, and 56.1% were men. About 44% experienced five or more lifetime manic episodes, and a third were diagnosed with mixed features. Both groups had severe mania at baseline according to mean YMRS scores.
Nearly twice as many participants in the lumateperone group achieved treatment response, defined as a 50% or greater reduction in YMRS score (43.9% vs 23.7%, P<0.0001). More patients on treatment also met qualifications for remission, defined as a YMRS score of 12 or less (25.4% vs 16.4%, P=0.0330).
"The efficacy, tolerability, and safety record accords with what we have seen previously in bipolar depression and schizophrenia," said McIntyre.
The most common treatment-emergent adverse events with lumateperone versus placebo were dizziness (10.4% vs 1.7%), dry mouth (5.8% vs 1.1%), and somnolence (5.2% vs 1.7%). Discontinuation rates due to adverse events were low (4.0% vs 3.4%).
来源:MedPage Today · medpagetoday.com